The EU butts heads with Big Pharma to make medicines cheaper

By HEOR Staff Writer

February 2, 2023

EU Pharmaceutical Regulations Proposal

The new EU proposal to revamp its pharmaceutical regulations. The main aim is to give people a better and more affordable access to medicines.

From what I can see, there are mixed feelings about the proposal. On one hand, consumer groups and civil society organizations are applauding the EU’s efforts to make medicines more accessible. On the other hand, the pharmaceutical industry is a bit skeptical.

So, what’s in the proposal? Well, the EU is looking to shorten the period in which pharmaceutical companies can sell their medicines without competition from 10 years to just 8 years. They’re also working towards closing the gap in access to medicines among different EU member states.

It’s interesting to see how this will all play out. What are your thoughts on the EU Pharmaceutical Regulations Proposal?

Reference url

Recent Posts

European pharmacists preparation
European Pharmacists Preparation for Health Crisis Response

By João L. Carapinha

May 29, 2026

European pharmacists preparation ensures that community networks remain operational during health crises, enabling continuous patient care amid pandemics and infrastructure failures. The recently published PGEU position paper outlines seven priorities that integrate pharmacies into governance str...
Radioligand Therapy Prostate Cancer
Advancements in Radioligand Therapy Prostate Cancer Treatment
Radioligand Therapy Prostate Cancer has emerged as a breakthrough approach in prostate cancer treatment by linking a cancer-targeting molecule to a radioactive payload that delivers radiation directly to tumor cells. This method minimizes damage to nearby healthy tissue while demonstrating clinic...
Conversational Agent Interventions
Therapeutic Impact of Conversational Agent Interventions on Mental Health
Conversational Agent Interventions demonstrate measurable benefits for mental health, according to a meta-analysis of 48 randomized controlled trials involving 28,071 participants that found both AI-based and rule-based agents produced small-to-moderate reductions in depression (SMD −0.27), anxie...